Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
2022 | journal article; research paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial
Levin, J.; Sing, N.; Melbourne, S.; Morgan, A.; Mariner, C.; Spillantini, M. G. & Wegrzynowicz, M. et al. (2022)
eBioMedicine, 80 art. S2352396422002055. DOI: https://doi.org/10.1016/j.ebiom.2022.104021
Documents & Media
1-s2.0-S2352396422002055-main.pdf597.85 kBAdobe PDF1-s2.0-S2352396422002055-mmc1.docx81.42 kBMicrosoft Word XML1-s2.0-S2352396422002055-mmc2.pptx61.69 kBMicrosoft Powerpoint XML
Details
- Authors
- Levin, Johannes; Sing, Nand; Melbourne, Sue; Morgan, Amber; Mariner, Carla; Spillantini, Maria Grazia; Wegrzynowicz, Michal; Dalley, Jeffrey W.; Langer, Simon; Ryazanov, Sergey ; Giese, Armin
- Issue Date
- 2022
- Journal
- eBioMedicine
- Project
- EXC 2067: Multiscale Bioimaging
- Working Group
- RG Griesinger
- ISSN
- 2352-3964
- Language
- English
